EACR Sponsored Session - Brain Tumors 2018: From Biology to Therapy

posted Feb 23, 2018, 1:48 AM by Kacper Walentynowicz   [ updated Feb 23, 2018, 1:49 AM ]

We are thrilled to announce that our application for EACR Sponsorship of our Conference has been successful. You can find our Conference on the EACR website (link_here).

This is the fourth international conference focused on recent findings and achievements in brain tumor biology and therapy. It consists of four sessions: Brain tumor pathobiology and diagnosis; Signaling in brain tumors; Glioma immunology and immunotherapy; Emerging brain tumor therapies. The main aim of the conference is the evaluation of current state of the art research in diagnosis, biology and therapy of brain tumours. Complex interactions between tumor cell, microenvironment and host immunity will be discussed. The collegial environment will foster interdisciplinary cross-talks and spark new scientific collaborations. Thanks to its high scientific quality, avoidence of parallel scientific sessions, specialized topics focused on basic and clinical research on brain tumor biology and therapy, it will provide an exceptional chance for extending knowledge and catching up with recent advances in innovative therapies of these deadly tumors.

The invited speakers are internationally recognized experts in the field of neuro-oncology. Usually neuro-oncology conferences are very clinically oriented, while this conference puts the emphasis on biology and the cellular and molecular mechanisms of brain tumor pathology.

The conference provides unique opportunities for students and young investigators to present posters and be selected for short talks. There is a low registration fee for young researchers to enhance their participation.



posted Feb 9, 2018, 12:19 PM by Kacper Walentynowicz   [ updated Mar 9, 2018, 2:30 AM ]

We are looking for a talented and highly motivated PhD student to complete a project entitled 'Reprogramming antitumor innate immunity in gliomas with osteopontin/Spp1 interfering peptides and nanovehicles-delivered siRNA/shRNA'.

The successful candidate should be fluent in English and hold MSc in Biology or related subject, have very good interpersonal skills, and ability to work in the interdisciplinary team. Hands-on experience in relevant techniques will be highly beneficial.

Please find more detail on the nencki.gov.pl website.

The project is funded by the National Science Centre (NCN).

Postdoctoral position at Kaminska's lab - RECRUITING

posted Dec 6, 2017, 1:35 AM by Kacper Walentynowicz   [ updated Dec 6, 2017, 1:35 AM ]

A 2.5-year postdoctoral position in SYMFONIA 3 project (supported by NCN; 6500 PLN) is available in the laboratory of Prof. Bozena Kaminska (www.kaminska-lab.pl), to participate in original biomedical research using ATCAseq, ChIPseq, DNA sequencing, DNA methylation profiling, high-throughput screening techniques. He/she will work in a joint computational and experimental environment with excellent resources for experimental validation of hypotheses generated by genomic analysis. The successful applicant will assume a leadership role in the pursuit of research in genetic and epigenetic dysfunctions in brain tumors by genome-wide mapping of non-coding, putative regulatory sites and their functional characterization; biochemical and molecular characterization of genetic and epigenetic mechanisms underlying dysfunctions. The postdoctoral fellow will apply state-of-the-art high throughput methods (ATAC-seq, DNA-Seq, RNA-Seq, ChIP-seq) and reverse genetic methodologies. She/he will have opportunities to attend international conferences, and participate in workshops and other career development programs in preparation for a leadership role in academia or industry.


The optimal postdoctoral researcher (up to 5 years after PhD), is enthusiastic and highly motivated to pursue a career in academic research. Qualifications: Ph.D. in Genetics or Molecular Biology. Preferred experience in biochemical, genetic and analysis of epigenetic histone modifications and/or sequence-specific DNA binding proteins. Applicants should have a strong publication record, including first authorship. Prior experience mentoring graduate and undergraduate students is highly appreciated.

Interested candidates should contact Prof. Bozena Kaminska b.kaminska@nencki.gov.pl with their CV and any questions about the research and the lab.

Deadline for applications is December 30, 2017; personal interviews with preselected candidates will be planned.  Starting date is negotiable but not later than February 1, 2018.

OPUS 13 for Dr Aleksandra Ellert-Miklaszewska

posted Nov 24, 2017, 1:43 AM by Kacper Walentynowicz   [ updated Nov 24, 2017, 2:00 AM ]

We are pleased to inform that Dr Aleksandra Ellert-Miklaszewska has received NCN flagship OPUS 13 grant (1 mln PLN) from the National Centre for Polish Science.

The project entitled 'Reprogramming antitumor innate immunity in gliomas with osteopontin/Spp1 interfering peptides and nanovehicles-delivered siRNA/shRNA' will investigate the interaction between tumor cells and components of its microenvironment. We have recently showed that tumor-derived protein, called osteopontin,contributes to tumor progression by attracting brain resident microglia and macrophages (GAMs) and shaping immune response in glioblastomas–the most malignat brain tumors. This 'bad education' of GAMs and other innate immune cells to tumor-supporting cells is not permanent and could be reversed bringing back antitumor immunity.Recent data suggest that high amounts of osteopontin detected inthe tumors may be derived notonly from the tumor cells but also from the host cells.Therefore, the main objective of the current project is to analyse the antitumor and immunomodulatory potency of systemic elimination of osteopontin either by genetic tools or using a peptide, which will block osteopontin action.


Summer placement at our laboratory

posted Aug 21, 2017, 2:39 AM by Kacper Walentynowicz   [ updated Aug 21, 2017, 2:39 AM ]

We are pleased to have welcomed international students at our laboratory over the summer break. We hope you have learnt a lot and the time spent at the Laboratory of Molecular Neurobiology was not only fruitful in acquiring new skills and knowledge but also showed you a day-today life of scientists at different stages of their carrier. Obtained skills in molecular and cell biology will give you best head-start in your future research projects.  Nevertheless, we hope that in the future, you will look back with a smile at the time spent at the Nencki Institute.

Best of luck with your future plans!

Students were part of:
University of Nottingham, UK
Columbia University, USA
University of Portsmouth, UK
Medical University of Łódź, PL

NCN POLONEZ Grant for Dr Jakub Mieczkowski

posted Jun 4, 2017, 9:57 AM by Kacper Walentynowicz   [ updated Jun 4, 2017, 10:05 AM ]

We are proud to announce that Dr Jakub Mieczkowski has received a grant from the National Science Centre called 'POLONEZ' (eng. Polonaise). This grant is directed towards researchers of Polish origin coming back to Poland after long research career abroad.
The funding for the project entitled 'Identification of epigenetic mechanisms contributing to glioma drug resistance' reaches almost 1 MILION PLN.

'The aim of this project is to identify epigenetic characteristics of glioblastoma stem-like cells and regulatory networks that contribute to tumor drug resistance and reoccurrence. First, epigenetic characteristics and gene expression levels will be profiled in glioblastoma stem-like cells and differentiated cells derived from them'

Further description of the project can be found in the pdf file attached.

We have celebrated this great news by having a small pizza party! Congratulations to Dr Mieczkowski and we wish fruitful results!

Brain Tumor 2017 Berlin Meeting

posted May 24, 2017, 7:07 AM by Kacper Walentynowicz   [ updated May 30, 2017, 12:51 AM ]

Our lab has visited our collaborators in Berlin at the The Max Delbrück Center for Molecular Medicine to attend the Brain Tumor Meeting 2017.

At the conference, we had a chance to present our recent data on minocycline and its potential therapeutic effect in rat glioma model. The presentation was given by Dr Anna Gieryng who leads the project on potential minocycline therapy.

We were also selected to present 4 posters at the poster session that included many researchers from around the world.
Posters were presented by:
* Dr Iwona Ciechomska 'Exploring glioma heterogeneity using immunoblotting and immunohistochemistry.'
* Dr Aleksandra Ellert-Miklaszewska 'Expression and function of NFAT nuclear factor of activated T cells transcription factors in human gliomas.'
* Karolina Stępniak 'Open chromatin and epigenetic landscape of human benign and malignant gliomas.'
* Bartłomiej Gielniewski 'The impact of IDH1/2 mutations on SOCS gene methylation and deregulation of STAT signalling in gliomas.'

FNP funded project TEAM TECH - recruiting Post doc and 3 PhD students

posted May 9, 2017, 6:39 AM by Kacper Walentynowicz   [ updated May 23, 2017, 1:49 AM ]

We are seeking candidates for postdoc  and 3 PhD students to participate in TEAM TECH Core Facility project entitled 'Dissecting pathobiology of pediatric brain tumors' (supported by FNP).

Researchers will participate in cutting-edge biomedical research using DNA sequencing, DNA methylation profiling, high-throughput screening techniques, and cell- and animal-based models. The project takes 3 years, starting from June 1, 2017.

Detailed information is enclosed in the attachment (pdf file below).

Deadline for the application is 27 May 2017 (PhD students) 25 June 2017 (post-doc).

Please send your CV to Prof Bozena Kaminska (b.kaminska@nencki.gov.pl) and any enquires regarding the posts and laboratory.

Dr Ciechomska seminar at the Department of Biochemistry

posted Mar 14, 2017, 1:31 AM by Kacper Walentynowicz   [ updated Mar 14, 2017, 1:32 AM ]

Today, Dr Iwona Ciechomska presented her recently published paper at the Departmental seminar. The paper entitled 'BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells.' published in Scientific Reports (IF 5.5) shed a light on BIX01294 mechanism in sensitization of glioma stem-like cells to temozolomide (currently a first-line therapeutic).
BIX01294 is an inhibitor of G9a histone methyltransferase (introducing H3K9me2 and H3K27me3 repressive marks) triggering autophagy in human glioma cells. This preliminary work can have a potential therapeutic application in GBM patients.

For more information see: Ciechomska et al. (2016) BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells. Sci Rep [ PubMed ]

Masters thesis in our lab!

posted Dec 5, 2016, 5:45 AM by Kacper Walentynowicz   [ updated Dec 5, 2016, 5:45 AM ]

We are seeking highly motivated MSc students to complete their research projects in one of our subjects:

Histopathology of rat gliomas following experimental therapies.

DNA methylation as a diagnostic biomarker.
Epigenetic changes in glioma cancer stem cells.
Whole genome open chromatin analysis of differentiating glioma cancer stem cells.

You are required to have very good written and spoken English.

Please send your CV and covering letter to:
Prof. Bozena Kaminska

1-10 of 19